Original Notice.

     Preproposal statement of inquiry was filed as WSR 03-09-124.

     Title of Rule and Other Identifying Information: WAC 246-887-170, amending the section to include carisoprodol in Schedule IV of the Uniform Controlled Substances Act.

     Hearing Location(s): Fife Community Center, 2111 54th Avenue East, Fife, WA 98424, on September 17, 2009, at 9 a.m.

     Date of Intended Adoption: September 17, 2009.

     Submit Written Comments to: Tim Fuller, P.O. Box 47863, Olympia, WA 98504-7863, web site http://www3.doh.wa.gov/policyreview/, fax (360) 236-2901, by September 3, 2009.

     Assistance for Persons with Disabilities: Contact Doreen Beebe by September 3, 2009, TTY (800) 833-6388 or 711.

     Purpose of the Proposal and Its Anticipated Effects, Including Any Changes in Existing Rules: The proposed rule places a drug that is being increasingly abused into the controlled substances Schedule IV. Placing carisoprodol in a controlled substances schedule will increase practitioners knowledge of carisoprodol and reduce abuse.

     Reasons Supporting Proposal: The experience with carisoprodol is that it is not only abused, but is documented to be increasingly abused. The data supporting the abuse comes from both national and local drug abuse tracking systems.

     Statutory Authority for Adoption: RCW 18.64.005(7), 69.50.201.

     Statute Being Implemented: RCW 69.50.201.

     Rule is not necessitated by federal law, federal or state court decision.

     Name of Proponent: Washington state board of pharmacy, governmental.

     Name of Agency Personnel Responsible for Drafting: Tim Fuller, 310 Israel Road S.E., Tumwater, (360) 236-4827; Implementation and Enforcement: Susan Boyer, 310 Israel Road S.E., Tumwater, (360) 236-4853.

     No small business economic impact statement has been prepared under chapter 19.85 RCW. The proposed rule would not impose more than minor costs on businesses in an industry.

     A cost-benefit analysis is required under RCW 34.05.328. A preliminary cost-benefit analysis may be obtained by contacting Tim Fuller, P.O. Box 47863, Olympia, WA 98504, phone (360) 236-4827, fax (360) 236-2901, e-mail tim.fuller@doh.wa.gov.

August 4, 2009

Susan Leil Boyer

Executive Director

Board of Pharmacy

OTS-2517.1

AMENDATORY SECTION(Amending WSR 98-02-084, filed 1/7/98, effective 1/7/98)

WAC 246-887-170   Schedule IV.   The board finds that the following substances have a low potential for abuse relative to substances in Schedule III and have currently accepted medical use in treatment in the United States and that the abuse of the substances may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III. The board, therefore, places each of the following substances in Schedule IV.

     (a) The drugs and other substances listed in this section, by whatever official name, common or usual name, chemical name, or brand name designated, are included in Schedule IV.

     (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

     (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

     (2) Dextropropoxyphene (alpha-(+)-e-dimethylamino-1,2-diphenyl-3-methyl-2 propionoxybutane).

     (c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1) Alprazolam;

     (2) Barbital;

     (3) Bromazepam;

     (4) Camazepam;

     (5) Carisoprodol;

     (6) Chloral betaine;

     (((6))) (7) Chloral hydrate;

     (((7))) (8) Chlordiazepoxide;

     (((8))) (9) Clobazam;

     (((9))) (10) Clonazepam;

     (((10))) (11) Clorazepate;

     (((11))) (12) Clotiazepam;

     (((12))) (13) Cloxazolam;

     (((13))) (14) Delorazepam;

     (((14))) (15) Diazepam;

     (((15))) (16) Estazolam;

     (((16))) (17) Ethchlorvynol;

     (((17))) (18) Ethinamate;

     (((18))) (19) Ethyl loflazepate;

     (((19))) (20) Fludiazepam;

     (((20))) (21) Flunitrazepam;

     (((21))) (22) Flurazepam;

     (((22))) (23) Halazepam;

     (((23))) (24) Haloxazolam;

     (((24))) (25) Ketazolam;

     (((25))) (26) Loprazolam;

     (((26))) (27) Lorazepam;

     (((27))) (28) Lormetazepam;

     (((28))) (29) Mebutamate;

     (((29))) (30) Medazepam;

     (((30))) (31) Meprobamate;

     (((31))) (32) Methohexital;

     (((32))) (33) Methylphenobarbital (mephobarbital);

     (((33))) (34) Midazolam;

     (((34))) (35) Nimetazepam;

     (((35))) (36) Nitrazepam;

     (((36))) (37) Nordiazepam;

     (((37))) (38) Oxazepam;

     (((38))) (39) Oxazolam;

     (((39))) (40) Paraldehyde;

     (((40))) (41) Petrichloral;

     (((41))) (42) Phenobarbital;

     (((42))) (43) Pinazepam;

     (((43))) (44) Prazepam;

     (((44))) (45) Quazepam;

     (((45))) (46) Temazepam;

     (((46))) (47) Tetrazepam;

     (((47))) (48) Triazolam;

     (((48))) (49) Zolpidem.

     (d) Fenfluramine. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position or geometric), and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible.

     (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1) Cathine ((+) - norpseudoephedrine);

     (2) Diethylpropion;

     (3) Fencamfamin;

     (4) Fenproporex;

     (5) Mazindol;

     (6) Mefenorex;

     (7) Pemoline (including organometallic complexes and chelates thereof);

     (8) Phentermine;

     (9) Pipradrol;

     (10) SPA ((-)-1-dimethylamino-1, 2-dephenylethane.

     (f) Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts:

     (1) Pentazocine;

     (2) Butorphanol.

[98-02-084 § 246-887-170, filed 1/7/98, effective 1/7/98. Statutory Authority: RCW 18.64.005. 94-08-098, § 246-887-170, filed 4/6/94, effective 5/7/94; 92-04-029 (Order 239B), § 246-887-170, filed 1/28/92, effective 2/29/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. 91-18-057 (Order 191B), recodified as § 246-887-170, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 69.50.201. 89-17-023 (Order 226), § 360-36-440, filed 8/8/89, effective 9/8/89. Statutory Authority: RCW 69.50.201, 69.50.203, 69.50.205, 69.50.207, 69.50.209 and 69.50.211. 84-22-062 (Order 190), § 360-36-440, filed 11/7/84.]

© Washington State Code Reviser's Office